Comparative Pharmacology
Head-to-head clinical analysis: ALLAY versus DOXYLAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLAY versus DOXYLAMINE.
ALLAY vs Doxylamine
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALLAY (clarithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide chain elongation.
Doxylamine is a first-generation antihistamine with sedative properties. It acts as a competitive antagonist at histamine H1 receptors, thereby blocking the effects of histamine. It also possesses anticholinergic activity.
ALLAY is a brand name for metoclopramide. Typical adult dose: 10 mg orally 4 times daily (30 minutes before meals and at bedtime). Alternatively, 10 mg intramuscularly or intravenously over 1-2 minutes. Maximum 30 mg/day (except for treatment of chemotherapy-induced emesis: 1-2 mg/kg IV 30 minutes before chemotherapy, then every 2 hours for 2 doses, then every 3 hours for 3 doses).
12.5–25 mg orally at bedtime for insomnia; 25 mg orally every 4–6 hours as needed for allergies (max 150 mg/day).
None Documented
None Documented
Clinical Note
moderateDoxylamine + Venlafaxine
"The risk or severity of adverse effects can be increased when Doxylamine is combined with Venlafaxine."
Clinical Note
moderateDoxylamine + Nefazodone
"The risk or severity of adverse effects can be increased when Doxylamine is combined with Nefazodone."
Clinical Note
moderateDoxylamine + Tranylcypromine
"Doxylamine may increase the anticholinergic activities of Tranylcypromine."
Clinical Note
moderateDoxylamine + Sertraline
Terminal half-life 8-12 hours in adults; prolonged to 18-24 hours in elderly or moderate hepatic impairment (Child-Pugh class B).
10-12 hours; prolonged in elderly and hepatic impairment.
Primarily renal excretion of unchanged drug (60-70%) and glucuronidated metabolites (10-15%); biliary/fecal elimination accounts for 10-20%.
Renal (approximately 60% as unchanged drug and metabolites, primarily as N-desmethyldoxylamine and other metabolites); biliary/fecal (minor).
Category C
Category A/B
Antihistamine (Sedating)
Antihistamine (Sedating)
"The risk or severity of adverse effects can be increased when Doxylamine is combined with Sertraline."